Pediatricians increasingly are recognizing a mandate to treat pain aggressively. Psychotropic drugs have new pediatric uses, broadening clinicians' options.
Arcutis submits roflumilast 0.15% sNDA for AD in children 6 years and up
Positive topline results from a pair of identical phase 3 trials support the submission of a supplemental New Drug Application to the FDA for Arcutis Biotherapeutics’ roflumilast cream 0.15%, a once-daily topical to treat mild to moderate atopic dermatitis (AD) in children 6 years or older.
Recognize & Refer: Hemangiomas in pediatrics
Contemporary Pediatrics sits down exclusively with Sheila Fallon Friedlander, MD, a professor dermatology and pediatrics, to discuss the one key condition for which she believes community pediatricians should be especially aware-hemangiomas.
Alopecia in adolescents
Hair loss is a condition that is often distressing and difficult to treat, particularly in adolescents. Here’s what you should know.
Discussing VP-102 to treat molluscum contagiosum in patients 2 years and up
In this Contemporary Pediatrics interview, Bernard A. Cohen, MD, discusses VP-102, approved by the FDA on July 22, 2023, to treat molluscum contagiosum in pediatric patients 2 years and up.
Masters of pediatric dermatology course offered to healthcare providers
The fully online training program, the MOPD Foundations of Pediatric Dermatology Certificate Course, was created by the founders of the Masters of Pediatric Dermatology (MOPD) Symposium and includes lectures, presentations, and downloadable resources for clinicians.
FDA approves VP-102 to treat molluscum contagiosum
Following the resubmission of a new drug application, the FDA has approved VP-102 to treat molluscum contagiosum, a contagious skin disease transmitted through direct skin-to-skin contact that primarily affects children.
2 Clarke Drive Cranbury, NJ 08512